Compare INSP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | CRVS |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2018 | 2016 |
| Metric | INSP | CRVS |
|---|---|---|
| Price | $41.89 | $11.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $94.00 | $30.17 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,050,000.00 | N/A |
| Revenue This Year | $8.02 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.18 | N/A |
| 52 Week Low | $38.91 | $3.55 |
| 52 Week High | $147.03 | $26.95 |
| Indicator | INSP | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 37.20 |
| Support Level | $39.61 | $11.42 |
| Resistance Level | $44.98 | $14.00 |
| Average True Range (ATR) | 2.33 | 0.80 |
| MACD | 0.26 | -0.08 |
| Stochastic Oscillator | 49.92 | 17.05 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.